Privia Health Group CFO Sells $283,000 Worth of Shares to Cover Taxes
Key Points
Privia Health's CFO sold 13,018 direct shares for approximately $283,000 over two days, at an average price of $21.71 per share.
The sale represented 5.24% of the CFO's total direct holdings as of the transaction dates.
- 10 stocks we like better than Privia Health Group ›
David Mountcastle, EVP & Chief Financial Officer of Privia Health Group (NASDAQ:PRVA), reported the direct sale of 13,018 shares over March 12 and March 13, 2026, for a total transaction value of approximately $283,000 according to a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 13,018 |
| Transaction value | $283,000 |
| Post-transaction shares (direct) | 226,804 |
| Post-transaction shares (indirect) | 8,695 |
| Post-transaction value (direct ownership) | ~$4.92 million |
Transaction value based on SEC Form 4 weighted average purchase price ($21.71); post-transaction value based on March 13, 2026 market close ($21.68).
Key questions
- What was the impact on Mountcastle’s ownership percentage and remaining share capacity?
The transaction reduced his direct holdings by 5.24%, leaving Mountcastle with 226,804 directly held shares and a remaining direct ownership stake of 0.18% of the company’s outstanding shares as of the filing. - Were there any indirect or derivative mechanics involved in this transaction?
No indirect or derivative securities were involved; the transaction consisted entirely of direct open-market sales, with indirect holdings (8,695 shares via spouse) unchanged by this filing.
Company overview
| Metric | Value |
|---|---|
| Market capitalization | $2.61 billion |
| Revenue (TTM) | $2.12 billion |
| Net income (TTM) | $22.92 million |
| 1-year price change (as of 3/21/26) | -10.15% |
Company snapshot
Privia Health Group operates as a national physician-enablement company, supporting over 1,100 employees and a broad network of providers. It offers technology platforms, population health tools, and management services to optimize physician practices and reduce the administrative burdens of independent physicians.
What this transaction means for investors
This sale of shares by Mountcastle was strictly for tax withholding obligations tied to the vesting of performance stock units, so investors shouldn’t let this transaction affect their investing decisions on PRVA stock. In a previous filing, the CFO had 35,335 restricted stock units vest on March 10, while 42,584 performance stock units vested the next day. So a sale to cover taxes was likely imminent. The EVP even sold 6,391 more shares on the 16th, at $22.11 per share, for a total of $141,241, which was also to cover taxes.
While PRVA share prices are down 10% in 2026, the company’s financials were fairly strong in its Q4 FY 2025 earnings report in late February. Privia exceeded earnings expectations, posting 7 cents per share for the quarter, above the 4-cent estimate and the highest year-over-year (YoY) growth since Q3 2023.
Privia is still looking to grow its value-based operations, as it’s highly optimistic about its acquisition of Accountable Care Organization (ACO) back in late September 2025. With the purchase, Privia gained approximately 1.5 million customers who possess medical plans such as Medicare, Medicare Advantage, and Medicaid.
Should you buy stock in Privia Health Group right now?
Before you buy stock in Privia Health Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Privia Health Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $495,179!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,058,743!*
Now, it’s worth noting Stock Advisor’s total average return is 898% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 22, 2026.
Adé Hennis has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
